Analystreport

Marker Therapeutics, Inc. (NASDAQ: MRKR) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.

Marker Therapeutics, Inc.  (MRKR) 
Last marker therapeutics, inc. earnings: 11/12 04:01 pm Check Earnings Report